UPSTREAM BIO, INC. (UPB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 9.99M USD | Liabilities, Current |
| Cash and equivalents | 79.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 772.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.99M | $79.40M | (m) | $772.00K | (m) | (m) |
| 2026-03-31 | (m) | $13.67M | $96.72M | (m) | $1.03M | (m) | (m) |
| 2025-12-31 | (m) | $13.45M | $101.58M | (m) | $668.00K | (m) | (m) |
| 2025-09-30 | (m) | $11.91M | $72.16M | (m) | $683.00K | (m) | (m) |
| 2025-06-30 | (m) | $10.93M | $45.46M | (m) | $937.00K | (m) | (m) |
| 2025-03-31 | (m) | $9.57M | $71.31M | (m) | $566.00K | (m) | (m) |
| 2024-12-31 | (m) | $10.74M | $325.89M | (m) | $613.00K | (m) | (m) |
| 2024-09-30 | (m) | $10.87M | $32.95M | (m) | $607.00K | (m) | (m) |
| 2024-06-30 | (m) | (m) | $47.34M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $31.51M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.51M | $25.83M | (m) | $98.00K | (m) | (m) |
| 2023-09-30 | (m) | (m) | $47.32M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |